Analyzing Unusual Options Activity for Humana Stock

What Humana’s Options Activity Is Telling Us
Options trading often acts like a quick read on sentiment, revealing where traders think a stock might go next and how confident they are. Lately, Humana (HUM) has seen a noticeable pickup in options activity. That uptick—unusual in its size and rhythm—suggests a mix of strategies playing out across healthcare, with traders positioning for both risk and opportunity.
Current Activity on the Tape
Here’s the split we’re seeing right now: 40% of trades lean bullish, while 30% tilt bearish. The rest fall outside those buckets, reflecting more nuanced positioning. Among the standout moves, two put options totaling $256,727 crossed the tape, alongside eight call options that added up to $527,825. Net-net, the balance tilts optimistic, even as some traders hedge against downside.
Where Traders See Price Risk
Looking at volumes alongside Open Interest over the past three months, the $310.0 to $360.0 range stands out as the key battleground. That band has drawn attention from active traders, who appear to be using it as a reference for near-term swings and risk.
Volume and Open Interest, Put in Context
Liquidity looks healthy in Humana’s options. Mean open interest sits at 158.14, with total trading volume at 1,190. Those figures point to engaged participation—enough depth to enter and exit positions without too much slippage—while also hinting at steady confidence in using options to express a view on HUM.
Calls vs. Puts: What the Last 30 Days Show
Over the most recent 30-day window, large trades have picked up on both sides of the ledger. Interest in calls and puts has been climbing together, a pattern that can precede choppier price action. In short: more traders are paying for exposure, whether for protection, speculation, or both.
Notable Options Trades
A few trades stood out:
- Call option: A bullish position with an expected price of $350.00, totaling $173,500 in premium—an expression of confidence in upside.
- Put option: A cautious stance with a put priced at $315.00, aggregating $156,900, likely hedging against potential weakness.
- Additional call activity: Further bullish interest clustered around expected strike prices of $360.00, signaling traders are willing to pay for a push higher.
A Snapshot of Humana
Humana is one of the largest private health insurers in the U.S., with a core focus on Medicare Advantage. The company’s strength in government-sponsored programs shows up in its membership across Medicare Advantage, Medicaid, and the military’s Tricare program. It also offers stand-alone prescription drug plans for seniors on traditional Medicare, rounding out a broad set of services for older adults and government-covered populations.
What the Stock Looks Like Right Now
- Recent trading volume reached 723,088. HUM was up 0.54%, edging toward $345.62.
- Recent Relative Strength Index (RSI) readings suggest the shares may be nearing an oversold area, prompting some to eye potential entries.
- Earnings are on deck in 50 days, a date many traders will circle as they fine-tune positions.
How Analysts Are Framing the Next Move
Analyst commentary over the last month points to cautious optimism. Four analysts weighed in, with an average target price of $396.5. The tone varies, but the center of gravity is constructive:
- RBC Capital: Outperform, with a $400 target.
- Cantor Fitzgerald: A recent downgrade to Neutral, with a $395 target—more guarded, but not bearish.
- JP Morgan: Neutral, with a $396 target—acknowledging upside while flagging near-term uncertainty.
As always, options cut both ways. Calls can amplify gains, puts can provide insurance, and both can expire worthless. Traders who do well tend to size positions carefully, revisit their assumptions, and keep an eye on how volume and open interest shift. With Humana, the current read is mixed but leaning positive—more calls than puts in dollar terms, a clear price band to watch, and an earnings event in sight.
Frequently Asked Questions
What does recent options activity suggest about HUM?
The tape shows a mixed but generally optimistic stance: 40% of trades skew bullish versus 30% bearish, with more dollars flowing into calls than puts overall.
Why is the $310.0–$360.0 range important?
Over the last three months, volumes and open interest clustered around that band, marking it as a key area where traders expect price reactions.
How should I read the highlighted call and put trades?
The $350.00 call outlay ($173,500) signals appetite for upside, while the $315.00 put ($156,900) reflects hedging or a cautious view. Additional call interest near $360.00 reinforces that upward bias.
What stands out about Humana’s business?
Humana focuses on Medicare Advantage and other government-backed programs, with membership spanning Medicare Advantage, Medicaid, and Tricare, plus stand-alone prescription drug plans for seniors.
What near-term catalysts matter for HUM?
Watch the 50-day countdown to earnings, recent RSI readings approaching oversold, and any shift in the options balance between calls and puts around the $310.0–$360.0 range.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.